EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lung cancer-associated fibroblasts-mediated collagen deposition drives mediastinal lymph node metastasis in non-small cell lung cancer

Caoyang Chen, Yuqian Feng, Frankie Chi Fat Ko, Sze Kwan Lam, Sheng Yan, James Chung Man Ho

Frontiers in Oncology · 12.06.2025 · 15

DOI: 10.3389/fonc.2025.1597585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 12.06.2025. Verfasst von Caoyang Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Wuhan Fourth Hospital, Wuhan, Hubei, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Metastasis to mediastinal lymph nodes signifies an advanced stage of non-small cell lung cancer (NSCLC) and presents significant clinical challenges. Cancer-associated fibroblasts (CAFs) within the tumor microenvironment (TME) play a crucial role in tumor progression by promoting growth and invasion. However, the specific contributions of lung CAFs to mediastinal lymph node metastasis in NSCLC remain poorly understood. Moreover, no therapeutics currently target CAFs to combat mediastinal lymph node metastasis in NSCLC. This study aims to elucidate the precise roles of CAFs in these complex processes and to investigate innovative therapeutic strategies that target CAFs to suppress metastasis to mediastinal lymph nodes.

Methods

Normal human lung fibroblasts (MRC-5) were directly co-cultured with NSCLC cell lines (H358 and HCC827) to generate lung CAFs. These activated CAFs were identified using immunofluorescence, flow cytometry, and Western blotting. To model human mediastinal lymph node metastasis, orthotopic xenograft (OX) models were established by intrathoracically injecting NSCLC cells into the left lung of mice, either alone or in combination with lung CAFs. The viability of cancer cells and lung CAFs post-treatment with ABT-199, a Bcl-2 inhibitor, was evaluated using MTT assays. The therapeutic efficacy of ABT-199 was further assessed through oral gavage in OX models, focusing on its potential to prevent metastasis to mediastinal lymph nodes. Tumor growth was monitored longitudinally using micro-computed tomography (CT), and treatment response was evaluated in accordance with RECIST 1.1 criteria. Primary tumors and mediastinal lymph node metastases were analyzed using hematoxylin and eosin (H&E) staining for general morphology, supplemented by immunohistochemistry/immunofluorescence to detect specific protein markers. Fibrillar collagen deposition within the TME was quantified using picrosirius red staining (PRS).

Results

Activation of α-SMA, accompanied by a significant increase in Col 1A1 expression in MRC-5 cells, was successfully induced through a direct 14-day co-culture with NSCLC cell lines. Histological analysis revealed increased fibrotic tissue formation, enhanced fibrillar collagen deposition, peritumoral lymphangiogenesis, and mediastinal lymph node metastasis in CAFs-enriched orthotopic xenograft (OX) tumors compared to CAFs-devoid OX tumors. The viability of lung CAFs was dose-dependently inhibited by ABT-199 in vitro . A two-week treatment with ABT-199 (100mg/kg) led to a significant reduction in lung CAFs and lymphangiogenesis in the CAFs-enriched OX model. Furthermore, an eight-week treatment with ABT-199 (100mg/kg) significantly reduced fibrillar collagen deposition and inhibited the number of metastases to mediastinal lymph nodes in both CAFs-devoid and CAFs-enriched OX models.

Conclusions

In NSCLC, cancer cells induce the differentiation of resident normal lung fibroblasts into lung CAFs. These CAFs secrete excessive collagens within the TME, thereby promoting tumor lymphangiogenesis and facilitating metastasis to mediastinal lymph nodes. Our findings, based on modified OX models, suggest that targeting lung CAFs could effectively attenuate lymphatic dissemination in NSCLC.

Schlagwörter

Stichwörter der Autor:innen

NSCLCcancer-associated fibroblastslymphangiogenesismediastinal lymph node metastasisorthotopic xenograft model

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, Wuhan Fourth Hospital, Wuhan, Hubei, China.
  • Division of Respiratory Medicine, Department of Medicine, School of Clinical Medicine, The University of Hong Kong, Hongkong, Hong Kong SAR, China.
  • Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.

Zitieren

APA

Chen, C., Feng, Y., Ko, F. C. F., Lam, S. K., Yan, S., & Ho, J. C. M. (2025). Lung cancer-associated fibroblasts-mediated collagen deposition drives mediastinal lymph node metastasis in non-small cell lung cancer. Frontiers in Oncology, 15. https://doi.org/10.3389/fonc.2025.1597585

Vancouver

Chen C, Feng Y, Ko FCF, Lam SK, Yan S, Ho JCM. Lung cancer-associated fibroblasts-mediated collagen deposition drives mediastinal lymph node metastasis in non-small cell lung cancer. Frontiers in Oncology. 2025;15. doi:10.3389/fonc.2025.1597585

BibTeX
@article{Chen2025,
  author = {Chen, Caoyang and Feng, Yuqian and Ko, Frankie Chi Fat and Lam, Sze Kwan and Yan, Sheng and Ho, James Chung Man},
  title = {Lung cancer-associated fibroblasts-mediated collagen deposition drives mediastinal lymph node metastasis in non-small cell lung cancer},
  journal = {Frontiers in Oncology},
  year = {2025},
  volume = {15},
  doi = {10.3389/fonc.2025.1597585}
}
Kostenlos starten →